Aprinocarsen/cisplatin/gemcitabine may have activity in NSCLC

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1465, 2004-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine plus cisplatin for NSCLC

By  

Inpharma, Vol. 1, Iss. 1222, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Gemcitabine + cisplatin for NSCLC: genotype predicts survival

By  

Inpharma, Vol. 1, Iss. 1540, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Gemcitabine alone or in combination with cisplatin cost effective in NSCLC

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 363, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer

By Vansteenkiste Johan   Canon Jean-Luc   Riska Henrik   Pirker Robert   Peterson Patrick   John William   Mali Pekka   Lahn Michael  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 263-269

Springer Publishing Company

Access to resources Recommend Favorite

Gemcitabine plus vinorelbine superior in NSCLC

By  

Inpharma, Vol. 1, Iss. 1251, 2000-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite